Invo BioScience (INVO)
(Delayed Data from NSDQ)
$0.84 USD
+0.02 (2.18%)
Updated Aug 23, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INVO 0.84 +0.02(2.18%)
Will INVO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for INVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INVO
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates
Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates
INVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regenxbio (RGNX) Reports Q3 Loss, Lags Revenue Estimates
Invo BioScience Inc. (INVO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Invo BioScience Inc. (INVO) Upgraded to Buy: Here's What You Should Know
Other News for INVO
INVO BioScience GAAP EPS of -$0.62, revenue of $1.84M
INVO Stock Earnings: INVO Bioscience Reported Results for Q2 2024
INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA
INVO Bioscience reports Q2 EPS (62c) vs. ($3.06) last year
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session